Quintrio
Home

OPHTHALMIC GOODS

Bausch + Lomb Corporation

BLCO

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes brands like Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, and surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xiidra and Miebo that treat various eye complications.

Last trade $20.90
Day change +$0.02 (+0.10%)
Day range $20.78 – $21.21
Volume 329,285
Market cap $7.46B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$7.46B
Price / earnings
—
Price / book
1.16×
Price / sales
1.38×
EV / sales
2.22×
EV / EBITDA
13.04×

Profitability

Earnings per share
-$0.31
Return on assets
-0.8%
Return on equity
-1.72%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.79×
Current ratio
1.56×
Quick ratio
1.04×
Cash ratio
0.26×

Cash flow

Price / cash flow
13.47×
Price / free cash flow
29.62×
Free cash flow
$252M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for BLCO, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$1.38B$1.39B$1.24B$1.41B$1.28B$1.28B$1.14B$1.28B
Cost of revenue$486M$527M$483M$533M$510M$525M$482M$501M
Gross profit$889M$867M$761M$872M$771M$753M$655M$779M
Selling, general and administrative$556M$588M$544M$564M$528M$579M$563M$532M
Research and development$91M$114M$101M$94M$95M$96M$86M$93M
Total operating expenses$734M$784M$728M$685M$676M$764M$738M$648M
Operating income$155M$83M$33M$187M$95M-$11M-$83M$131M
Interest expense-$95M-$93M-$97M-$98M-$101M-$128M-$94M-$98M
Income before taxes$58M-$11M-$64M$13M-$3M-$147M-$180M-$10M
Income taxes$23M-$1M$6M$71M$22M-$89M$31M-$8M
Net income$35M-$10M-$70M-$58M-$25M-$58M-$211M-$2M
Net income attributable to common shareholders$32M-$14M-$71M-$58M-$28M-$62M-$212M-$3M
EBITDA$257M$185M$134M$348M$204M$96M$23M$319M
Basic earnings per share$0.09-$0.04-$0.20-$0.16-$0.08-$0.18-$0.60-$0.01
Diluted earnings per share$0.09-$0.04-$0.20-$0.16-$0.08-$0.18-$0.60-$0.01

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Best Growth Stocks to Buy for November 17th

Zacks highlights three stocks with Rank #1 (Strong Buy) ratings and strong growth characteristics: Expedia Group (EXPE) in online travel with a PEG ratio of 0.51 and 6.4% earnings estimate increase; Bausch + Lomb (BLCO) in eye health with a PEG ratio of 0.56 and 17.5% earnings estimate increase; and Crane Company (CR) in engineered industrial products with a PEG ratio of 2.15 and 4.4% earnings estimate increase.

Zacks Investment Research

Best Growth Stocks to Buy for November 13th

Zacks highlights three stocks with Rank #1 buy ratings and strong growth potential: Bausch + Lomb (eye health), Valero Energy (transportation fuels and petrochemicals), and Hasbro (toys and games). All three have seen consensus earnings estimates increase over the last 60 days and possess favorable PEG ratios compared to their respective industries.

Zacks Investment Research

Best Growth Stocks to Buy for November 11th

Zacks highlights three stocks with Rank #1 buy ratings and strong growth potential: Bausch + Lomb (eye health), Valero Energy (transportation fuels and petrochemicals), and Hasbro (toys and games). All three have seen consensus earnings estimates increase over the last 60 days, with favorable PEG ratios compared to their respective industries.

Zacks Investment Research

Best Growth Stocks to Buy for November 9th

Zacks highlights three stocks with Rank #1 buy ratings showing strong growth potential: Bausch + Lomb (eye health), Valero Energy (transportation fuels and petrochemicals), and Hasbro (toys and games). All three have seen consensus earnings estimates increase over the last 60 days, with Valero showing the strongest growth at 40.5%.

Zacks Investment Research

Zacks.com featured highlights include Repsol, Bausch + Lomb, DMC Global, Universal Logistics and Methanex

Following the U.S. midterm elections, the S&P 500 rallied on prospects of divided government and declining oil prices. Zacks highlights five stocks demonstrating strong relative price strength with positive earnings revisions: Repsol, Bausch + Lomb, DMC Global, Universal Logistics Holdings, and Methanex. All five companies have VGM Scores of A and show significant expected earnings growth for 2026.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.